← Back to patent-cliff list
CAS 10397-13-4
4-(4,6-dichloropyrimidin-2-yl)morpholine
Codes: BUPA-004
Application context (from source-drug indications)
Head and neck squamous cell carcinomaBuparlisibSolid tumourBuparlisib鼻咽肿瘤Buparlisib喉肿瘤Buparlisib口咽肿瘤BuparlisibSquamous cell carcinomaBuparlisib
Source drugs (routes using this intermediate)
| Drug | Tier | Expiry |
|---|---|---|
| Buparlisib | Tier C — Watch / trade | - |
Position in synthesis routes (up/downstream chain)
Ordered by route registration; left → right is the synthesis direction. The highlighted node is the current CAS; others link to their own profiles.
morpholine-4-carboximidamide hydrobromide→diethyl malonate→2-morpholinopyrimidine-4,6-diol→4-(4,6-dichloropyrimidin-2-yl)morpholine→4,4'-(6-chloropyrimidine-2,4-diyl)dimorpholine→5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-4-(trifluoromethyl)pyridin-2-amine→4-(trifluoromethyl)pyridin-2-amine→5-bromo-4-(trifluoromethyl)pyridin-2-amine→4,4,4',4',5,5,5',5'-octamethyl-2,2'-bi(1,3,2-dioxaborolane)
Intermediates available on this site
No listed intermediates for this target yet — send an RFQ directly and it will enter our matching pool.
This is a CAS-level registry record: registrations across routes are merged. Supplier offers and buyer demands will be matched on this CAS as the primary key.